Best Practice & Research Clinical Gastroenterology

Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). 90 Y-DOTATOC and 177 Lu- DOTATATE are the most used radiopeptides for PRRT with com- parable tumour response rates (about 15-35%). The side effects of this therapy are few and mild. However, amino acids should be used for kidney protection, especially during infusion of 90 Y-